Novel platinum compounds and nanoparticles as anticancer agents.

Area of Science:

• Medicinal Chemistry
• Oncology
• Patent Law

Background:

• Platinum-based drugs, like cisplatin, have been mainstays in cancer chemotherapy since 1979.
• Second- and third-generation platinum compounds (carboplatin, oxaliplatin) have expanded therapeutic options.
• Ongoing research focuses on new platinum drugs and formulations, with many in clinical trials.

Purpose of the Study:

• To review and analyze patent applications for novel platinum anticancer compounds.
• To provide an overview of recent innovations in platinum-based cancer therapeutics.
• To identify trends in the patent landscape of platinum anticancer agents from 2012 to 2017.

Main Methods:

• Systematic review of published patent applications.
• Focus on patent filings related to novel platinum anticancer compounds.
• Data collection period: 2012 to August 2017.

Main Results:

• Summary of patent filings for new platinum anticancer agents and formulations.
• Identification of key areas of innovation within platinum compound development.
• Overview of the patenting activity in the field during the specified period.

Conclusions:

• The patent landscape reflects continued innovation in platinum-based anticancer drug development.
• Analysis of patent trends offers insights into future therapeutic strategies.
• Understanding patent activity is crucial for researchers and the pharmaceutical industry.